Want a deeper scan?
Get a guided tour of your organization’s security posture from an UpGuard team member.

Cellectis

This is a preliminary report on Cellectis’s security posture. If you want in-depth, always up-to-date reports on Cellectis and millions of other companies, start a free trial today. UpGuard is the new standard in third-party risk management and attack surface management. Our security ratings engine monitors billions of data points each day.
Get the full report

UpGuard Security Rating

${grade.letter}
${cstarScore}
/ 950
This is a 0-950 security rating for Cellectis. The higher the rating, the more likely Cellectis has good security practices. For complete visibility of the security posture of Cellectis, start a free trial of UpGuard.

Company info

Cellectis
Company
Cellectis
Employees
Location
CEO
André Choulika
Last updated
Last updated
Industries
Last updated today

Security report for Cellectis

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy.
Get the full report
Last updated today

Cellectis Data Breaches and Security News

Relevant news, breaches and security articles relating to Cellectis.

More security reports

Compare Cellectis's security performance with other companies.

Leader in Third Party & Supplier Risk Management Software

See how UpGuard shapes up against other platforms in the market.
Free instant security score

How secure is your organization?

Request a free cybersecurity report to discover key risks on your website, email, network, and brand.
  • Check icon
    Instant insights you can act on immediately
  • Check icon
    Hundreds of risk factors including email security, SSL, DNS health, open ports and common vulnerabilities
Website Security scan resultsWebsite Security scan rating
Want a full vendor security report for this company?
Start your free trial and unlock real-time insights to identify and assess vendor risks.